Skip to main content
SpringerLink
Log in

Autologous Bone Marrow-Derived Cell Therapies for Retinal Disease

  • Chapter
  • First Online:
Cellular Therapies for Retinal Disease

  • 873 Accesses

Abstract

Autologous bone marrow-derived cell therapy is being explored in clinical trial as potential treatment for ischemic or degenerative retinal conditions. The rationale for exploring this therapy is that there is preclinical evidence showing that certain stem cells in bone marrow can have a regenerative effect on ischemic or degenerating retina. Direct tissue incorporation and paracrine trophic effects of bone marrow stem cells have been demonstrated in animal models. The cells in bone marrow that have been studied include mesenchymal stem cells, mononuclear cells, and CD34+ cells. These cells can be harvested easily from bone marrow. With autologous cell therapy, no systemic immunosuppression or donor matching is needed. Early reports of phase 1 clinical trials using intravitreal autologous bone marrow CD34+ or mononuclear cells show no safety or feasibility issues associated with the cell therapy. Larger studies are needed to determine the full safety profile and therapeutic potential of these cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bourne RR, Stevens GA, White RA, et al.; Vision Loss Expert Group. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1:e339–49.

    Google Scholar 

  2. Jonas JB, Bourne RR, White RA, et al.; Vision Loss Expert Group of the Global Burden of Disease Study. Visual impairment and blindness due to macular diseases globally: a systematic review and meta-analysis. Am J Ophthalmol. 2014;158:808–15.

    Google Scholar 

  3. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900–1.

    Article  CAS  PubMed  Google Scholar 

  4. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99:933–43.

    Article  CAS  PubMed  Google Scholar 

  5. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology. 1995;102:1450–60.

    Article  CAS  PubMed  Google Scholar 

  6. Klaver CC, Assink JJ, van Leeuwen R, et al. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2001;42:2237–41.

    CAS  PubMed  Google Scholar 

  7. Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115:116–26.

    Article  PubMed  Google Scholar 

  8. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology. 2010;117:921–7.

    Article  PubMed  Google Scholar 

  9. Rudnicka AR, Kapetanakis VV, Jarrar Z, et al. Incidence of late-stage age-related macular degeneration in American whites: systematic review and meta-analysis. Am J Ophthalmol. 2015;160:85–93.

    Article  PubMed  Google Scholar 

  10. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–16.

    Article  PubMed  Google Scholar 

  11. Roodhooft JM. Leading causes of blindness worldwide. Bull Soc Belge Ophtalmol. 2002;283:19–25.

    Google Scholar 

  12. Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res. 2012;47:171–88.

    Article  PubMed  Google Scholar 

  13. International Diabetes Federation. IDF Diabetes Atlas. 5th ed. Brussels: International Diabetes Federation; 2011.

    Google Scholar 

  14. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.

    Article  CAS  PubMed  Google Scholar 

  15. World Health Organization. Diabetes action now: an initiative of the World Health Organization and the International Diabetes Federation. Geneva: World Health Organization; 2004.

    Google Scholar 

  16. Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012;60:428–31.

    Article  PubMed  PubMed Central  Google Scholar 

  17. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol. 1996;114:545–54.

    Article  Google Scholar 

  18. Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006;1:40.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Blacharski PA. Fundus flavimaculatus. In: Newsome DA, editor. Retinal dystrophies and degenerations. New York: Raven Press; 1988. p. 135–59.

    Google Scholar 

  20. Xu L, Wang Y, Li Y, Wang Y, Cui T, Li J, Jonas JB. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology. 2006;113:1134.e1–11.

    Google Scholar 

  21. Iwase A, Araie M, Tomidokoro A, et al.; Tajimi Study Group. Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study. Ophthalmology. 2006;113:1354–62.

    Google Scholar 

  22. Wu L, Sun X, Zhou X, Weng C. Causes and 3-year-incidence of blindness in Jing-An District, Shanghai, China 2001–2009. BMC Ophthalmol. 2011;11:10.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Silva R. Myopic maculopathy: a review. Ophthalmologica. 2012;228:197–213.

    Article  PubMed  Google Scholar 

  24. Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet. 2014;15:151–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010;10:31.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology. 2004;111:1280–7.

    Article  PubMed  Google Scholar 

  27. Fritsche LG, Chen W, Schu M, et al.; AMD Gene Consortium. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013;45:433–39.

    Google Scholar 

  28. Grassmann F, Fritsche LG, Keilhauer CN, Heid IM, Weber BH. Modeling the genetic risk in age-related macular degeneration. PLoS One. 2012;7:e37979.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham eye study: I. Outline and major prevalence findings. Am J Epidemiol. 1977;106:17e32.

    Article  Google Scholar 

  30. Rosenfeld PJ, Brown DM, Heier JS, et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.

    Google Scholar 

  31. Brown DM, Kaiser PK, Michels M, et al.; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.

    Google Scholar 

  32. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98.

    Article  Google Scholar 

  33. Heier JS, Brown DM, Chong V, et al.; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.

    Google Scholar 

  34. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193–201.

    Article  PubMed  Google Scholar 

  35. Chakravarthy U, Harding SP, Rogers CA, et al.; IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomized controlled trial. Lancet. 2013;382:1258–67.

    Google Scholar 

  36. Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol. 2009;20:166–74.

    Article  PubMed  Google Scholar 

  37. Augood CA, Vingerling JR, de Jong PT, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol. 2006;124:529–35.

    Article  PubMed  Google Scholar 

  38. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114:253–62.

    Article  PubMed  Google Scholar 

  39. Chew EY, Clemons TE, Agrón E, et al.; Age-Related Eye Disease Study Research Group. Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology. 2013;120:1604–11.

    Google Scholar 

  40. Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, Clemons TE, Sangiovanni JP, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014;132:142–9.

    Article  CAS  Google Scholar 

  41. Wang JJ, Buitendijk GH, Rochtchina E, et al. Genetic susceptibility, dietary antioxidants, and long-term incidence of age-related macular degeneration in two populations. Ophthalmology. 2014;121:667–75.

    Article  PubMed  Google Scholar 

  42. Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013;2013:343560.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Brown DM, Nguyen QD, Marcus DM, et al.; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013–22.

    Google Scholar 

  44. Network DRCR, Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–203.

    Article  CAS  Google Scholar 

  45. Elman MJ, Ayala A, Bressler NM, et al.; Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122:375–81.

    Google Scholar 

  46. Do DV, Nguyen QD, Boyer D, et al.; da Vinci Study Group. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119:1658–65.

    Google Scholar 

  47. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 2-month data: report 3. Arch Ophthalmol. 2012;130:972–9.

    Article  CAS  PubMed  Google Scholar 

  48. Kriechbaum K, Prager S, Mylonas G, et al.; Diabetic Retinopathy Research Group. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye (Lond). 2014;28:9–15.

    Google Scholar 

  49. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121:2473–81.

    Article  PubMed  Google Scholar 

  50. Callanan DG, Gupta S, Boyer DS, et al.; Ozurdex PLACID Study Group. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013;120:1843–51.

    Google Scholar 

  51. Boyer DS, Yoon YH, Belfort R Jr, et al.; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–14.

    Google Scholar 

  52. Campochiaro PA, Hafiz G, Shah SM, et al.; FAME Study Group. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010;117:1393–99.

    Google Scholar 

  53. Fong DS, Ferris 3rd FL, Davis MD, Chew EY. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1999;127:137–41.

    Article  CAS  PubMed  Google Scholar 

  54. Tzekov R, Arden GB. The electroretinogram in diabetic retinopathy. Surv Ophthalmol. 1999;44:53–60.

    Article  CAS  PubMed  Google Scholar 

  55. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–9.

    Article  PubMed  Google Scholar 

  56. Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina. 2011;31:1877–84.

    Article  CAS  PubMed  Google Scholar 

  57. Ahn SJ, Ahn J, Park S, Kim H, et al. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2014;55:567–73.

    Article  CAS  PubMed  Google Scholar 

  58. Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154:682–6.

    Article  CAS  PubMed  Google Scholar 

  59. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012;32:434–57.

    CAS  PubMed  Google Scholar 

  60. Kim H, Csaky KG, Gravlin L, et al. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina. 2006;26:523–30.

    Article  PubMed  Google Scholar 

  61. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters 3rd GB, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681–6.

    Article  PubMed  Google Scholar 

  62. Conlon TJ, Deng WT, Erger K, et al. Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa. Hum Gene Ther Clin Dev. 2013;24:23–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Dinculescu A, Min SH, Deng WT, Li Q, Hauswirth WW. Gene therapy in the rd6 mouse model of retinal degeneration. Adv Exp Med Biol. 2014;801:711–8.

    Article  PubMed  Google Scholar 

  64. Ben M’Barek K, Regent F, Monville C. Use of human pluripotent stem cells to study and treat retinopathies. World J Stem Cells. 2015;7:596–604.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A. 2013;110:E517–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145–7.

    Article  CAS  PubMed  Google Scholar 

  67. Cui L, Guan Y, Qu Z, et al. WNT signaling determines tumorigenicity and function of ESC-derived retinal progenitors. J Clin Invest. 2013;123:1647–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Melville H, Carpiniello M, Hollis K, Staffaroni A, Golestaneh N. Stem cells: a new paradigm for disease modeling and developing therapies for age-related macular degeneration. J Transl Med. 2013;11:53.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Alonso-Alonso ML, Srivastava GK. Current focus of stem cell application in retinal repair. World J Stem Cells. 2015;7:641–8.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Booth C, Veys P. T cell depletion in paediatric stem cell transplantation. Clin Exp Immunol. 2013;172:139–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Schmeisser A, Strasser RH. Phenotypic overlap between hematopoietic cells with suggested angioblastic potential and vascular endothelial cells. J Hematother Stem Cell Res. 2002;11:69–79.

    Article  CAS  PubMed  Google Scholar 

  72. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol. 1976;4:267–74.

    CAS  PubMed  Google Scholar 

  73. Ashton BA, Allen TD, Howlett CR, Eaglesom CC, Hattori A, Owen M. Formation of bone and cartilage by marrow stromal cells in diffusion chambers in vivo. Clin Orthop Relat Res. 1980;151:294–307.

    Google Scholar 

  74. Bab I, Ashton BA, Gazit D, Marx G, Williamson MC, Owen ME. Kinetics and differentiation of marrow stromal cells in diffusion chambers in vivo. J Cell Sci. 1986;84:139–51.

    CAS  PubMed  Google Scholar 

  75. Castro-Malaspina H, Gay RE, Resnick G, et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood. 1980;56:289–301.

    CAS  PubMed  Google Scholar 

  76. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood. 2001;98:2396–402.

    Article  CAS  PubMed  Google Scholar 

  77. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13:4279–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25:2739–49.

    Article  CAS  PubMed  Google Scholar 

  79. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.

    Article  CAS  PubMed  Google Scholar 

  80. Yamanaka S, Takahashi K. Induction of pluripotent stem cells from mouse fibroblast cultures. Tanpakushitsu Kakusan Koso. 2006;51:2346–51.

    CAS  PubMed  Google Scholar 

  81. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–72.

    Article  CAS  PubMed  Google Scholar 

  82. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917–20.

    Article  CAS  PubMed  Google Scholar 

  83. Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell. 2008;134:877–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Wernig M, Meissner A, Foreman R, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007;448:318–24.

    Article  CAS  PubMed  Google Scholar 

  85. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313–7.

    Article  CAS  PubMed  Google Scholar 

  86. da Silva ML, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006;119:2204–13.

    Article  CAS  Google Scholar 

  87. Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev. 2012;21:2724–52.

    Article  CAS  PubMed  Google Scholar 

  88. Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells: a novel treatment modality for tissue repair. Ann N Y Acad Sci. 2009;1176:101–17.

    Article  CAS  PubMed  Google Scholar 

  89. Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011;9:12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol. 2006;24:150–4.

    Article  CAS  PubMed  Google Scholar 

  91. Noël D, Caton D, Roche S, et al. Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res. 2008;314:1575–84.

    Article  PubMed  CAS  Google Scholar 

  92. Pachón-Peña G, Yu G, Tucker A, et al. Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. J Cell Physiol. 2011;226:843–51.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  93. De Ugarte DA, Morizono K, Elbarbary A, et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs. 2003;174:101–9.

    Article  PubMed  Google Scholar 

  94. Sakaguchi Y, Sekiya I, Yagishita K, Muneta T. Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum. 2005;52:2521–9.

    Article  PubMed  Google Scholar 

  95. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24:1294–301.

    Article  CAS  PubMed  Google Scholar 

  96. Rezanejad H, Soheili ZS, Haddad F, et al. In vitro differentiation of adipose-tissue-derived mesenchymal stem cells into neural retinal cells through expression of human PAX6 (5a) gene. Cell Tissue Res. 2014;356:65–75.

    Article  CAS  PubMed  Google Scholar 

  97. Vossmerbaeumer U, Ohnesorge S, Kuehl S, et al. Retinal pigment epithelial phenotype induced in human adipose tissue-derived mesenchymal stromal cells. Cytotherapy. 2009;11:177–88.

    Article  CAS  PubMed  Google Scholar 

  98. Moviglia GA, Blasetti N, Zarate JO, Pelayes DE. In vitro differentiation of adult adipose mesenchymal stem cells into retinal progenitor cells. Ophthalmic Res. 2012;48(Suppl 1):1–5.

    Article  CAS  PubMed  Google Scholar 

  99. Singh AK, Srivastava GK, García-Gutiérrez MT, Pastor JC. Adipose derived mesenchymal stem cells partially rescue mitomycin C treated ARPE19 cells from death in co-culture condition. Histol Histopathol. 2013;28:1577–83.

    CAS  PubMed  Google Scholar 

  100. Xia J, Luo M, Ni N, et al. Bone marrow mesenchymal stem cells stimulate proliferation and neuronal differentiation of retinal progenitor cells. PLoS One. 2013;8:e76157.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Duan P, Xu H, Zeng Y, Wang Y, Yin ZQ. Human bone marrow stromal cells can differentiate to a retinal pigment epithelial phenotype when co-cultured with pig retinal pigment epithelium using a transwell system. Cell Physiol Biochem. 2013;31:601–13.

    Article  CAS  PubMed  Google Scholar 

  102. Huang C, Zhang J, Ao M, et al. Combination of retinal pigment epithelium cell-conditioned medium and photoreceptor outer segments stimulate mesenchymal stem cell differentiation toward a functional retinal pigment epithelium cell phenotype. J Cell Biochem. 2012;113:590–8.

    Article  CAS  PubMed  Google Scholar 

  103. Sun X, Chen M, Li J, et al. E13.5 retinal progenitors induce mouse bone marrow mesenchymal stromal cells to differentiate into retinal progenitor-like cells. Cytotherapy. 2011;13:294–303.

    Article  CAS  PubMed  Google Scholar 

  104. Tao YX, Xu HW, Zheng QY, FitzGibbon T. Noggin induces human bone marrow-derived mesenchymal stem cells to differentiate into neural and photoreceptor cells. Indian J Exp Biol. 2010;48:444–52.

    CAS  PubMed  Google Scholar 

  105. Yang LL, Zhou QJ, Wang Y, Wang YQ. Differentiation of human bone marrow-derived mesenchymal stem cells into neural-like cells by co-culture with retinal pigmented epithelial cells. Int J Ophthalmol. 2010;3:23–7.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Johnson TV, DeKorver NW, Levasseur VA, et al. Identification of retinal ganglion cell neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome. Brain. 2014;137:503–19.

    Article  PubMed  Google Scholar 

  107. Sugitani S, Tsuruma K, Ohno Y, et al. The potential neuroprotective effect of human adipose stem cells conditioned medium against light-induced retinal damage. Exp Eye Res. 2013;116:254–64.

    Article  CAS  PubMed  Google Scholar 

  108. Tsuruma K, Yamauchi M, Sugitani S, et al. Progranulin, a major secreted protein of mouse adipose-derived stem cells, inhibits light-induced retinal degeneration. Stem Cells Transl Med. 2014;3:42–53.

    Article  CAS  PubMed  Google Scholar 

  109. Zhang Y, Wang W. Effects of bone marrow mesenchymal stem cell transplantation on light-damaged retina. Invest Ophthalmol Vis Sci. 2010;51:3742–8.

    Article  PubMed  Google Scholar 

  110. Arnhold S, Absenger Y, Klein H, Addicks K, Schraermeyer U. Transplantation of bone marrow-derived mesenchymal stem cells rescue photoreceptor cells in the dystrophic retina of the rhodopsin knockout mouse. Graefes Arch Clin Exp Ophthalmol. 2007;245:414–22.

    Article  CAS  PubMed  Google Scholar 

  111. Li N, Li XR, Yuan JQ. Effects of bone-marrow mesenchymal stem cells transplanted into vitreous cavity of rat injured by ischemia/reperfusion. Graefes Arch Clin Exp Ophthalmol. 2009;247:503–14.

    Article  PubMed  Google Scholar 

  112. Hou HY, Liang HL, Wang YS, et al. A therapeutic strategy for choroidal neovascularization based on recruitment of mesenchymal stem cells to the sites of lesions. Mol Ther. 2010;18:1837–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Yang J, Zhou W, Zheng W, et al. Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology. 2007;107:17–29.

    Article  PubMed  Google Scholar 

  114. Matsumoto R, Omura T, Yoshiyama M, et al. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2005;25:1168–73.

    Article  CAS  PubMed  Google Scholar 

  115. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002;62:3603–8.

    CAS  PubMed  Google Scholar 

  116. Zhang XS, Linkhart TA, Chen ST, et al. Local ex vivo gene therapy with bone marrow stromal cells expressing human BMP4 promotes endosteal bone formation in mice. J Gene Med. 2004;6:4–15.

    Article  CAS  PubMed  Google Scholar 

  117. Tang TT, Xu XL, Dai KR, Yu CF, Yue B, Lou JR. Ectopic bone formation of human bone morphogenetic protein-2 gene transfected goat bone marrow-derived mesenchymal stem cells in nude mice. Chin J Traumatol. 2005;8:3–7.

    CAS  PubMed  Google Scholar 

  118. Hasharoni A, Zilberman Y, Turgeman G, Helm GA, Liebergall M, Gazit D. Murine spinal fusion induced by engineered mesenchymal stem cells that conditionally express bone morphogenetic protein-2. J Neurosurg Spine. 2005;3:47–52.

    Article  PubMed  Google Scholar 

  119. Park HY, Kim JH, Sun Kim H, Park CK. Stem cell-based delivery of brain-derived neurotrophic factor gene in the rat retina. Brain Res. 2012;1469:10–23.

    Article  CAS  PubMed  Google Scholar 

  120. Lee ES, Yu SH, Jang YJ, Hwang DY, Jeon CJ. Transplantation of bone marrow-derived mesenchymal stem cells into the developing mouse eye. Acta Histochem Cytochem. 2011;44:213–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Lu B, Wang S, Girman S, McGill T, Ragaglia V, Lund R. Human adult bone marrow-derived somatic cells rescue vision in a rodent model of retinal degeneration. Exp Eye Res. 2010;91:449–55.

    Article  CAS  PubMed  Google Scholar 

  122. Haddad-Mashadrizeh A, Bahrami AR, Matin MM, et al. Human adipose-derived mesenchymal stem cells can survive and integrate into the adult rat eye following xenotransplantation. Xenotransplantation. 2013;20:165–76.

    PubMed  Google Scholar 

  123. Tzameret A, Sher I, Belkin M, et al. Transplantation of human bone marrow mesenchymal stem cells as a thin subretinal layer ameliorates retinal degeneration in a rat model of retinal dystrophy. Exp Eye Res. 2014;118:135–44.

    Article  CAS  PubMed  Google Scholar 

  124. Tomita M, Adachi Y, Yamada H, et al. Bone marrow-derived stem cells can differentiate into retinal cells in injured rat retina. Stem Cells. 2002;20:279–83.

    Article  CAS  PubMed  Google Scholar 

  125. Otani A, Dorrell MI, Kinder K, et al. Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lineage-negative hematopoietic stem cells. J Clin Invest. 2004;114:765–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Mackie AR, Losordo DW. CD34 positive stem cells in the treatment of hear and vascular disease in human beings. Tex Heart Inst J. 2011;38:474–85.

    PubMed  PubMed Central  Google Scholar 

  127. Medina RJ, O’Neill CL, Sweeney M, Guduric-Fuchs J, Gardiner TA, Simpson DA, Stitt AW. Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Med Genet. 2010;3:18.

    Google Scholar 

  128. Madeddu P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol. 2005;90:315–26.

    Article  CAS  PubMed  Google Scholar 

  129. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000;97:3422–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–7.

    Article  CAS  PubMed  Google Scholar 

  131. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003;9:702–12.

    Article  CAS  PubMed  Google Scholar 

  132. Stitt AW, O’Neill CL, O’Doherty MT, Archer DB, Gardiner TA, Medina RJ. Vascular stem cells and ischaemic retinopathies. Prog Retin Eye Res. 2011;30:149–66.

    Article  CAS  PubMed  Google Scholar 

  133. Kim SJ, Kim JS, Papadopoulos J, et al. Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. Am J Pathol. 2009;174:1972–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Lois N, McCarter RV, O’Neill C, Medina RJ, Stitt AW. Endothelial progenitor cells in diabetic retinopathy. Front Endocrinol (Lausanne). 2014;5:44.

    Google Scholar 

  135. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007;109:1801–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Schuh A, Liehn EA, Sasse A, et al. Transplantation of endothelial progenitor cells improves neovascularization and left ventricular function after myocardial infarction in a rat model. Basic Res Cardiol. 2008;103:69–77.

    Article  PubMed  Google Scholar 

  137. Sasaki K, Heeschen C, Aicher A, et al. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci U S A. 2006;103:14537–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Nolan DJ, Ciarrocchi A, Mellick AS, et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev. 2007;21:1546–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Bhatwadekar AD, Glenn JV, Curtis TM, Grant MB, Stitt AW, Gardiner TA. Retinal endothelial cell apoptosis stimulates recruitment of endothelial progenitor cells. Invest Ophthalmol Vis Sci. 2009;50:4967–73.

    Article  PubMed  PubMed Central  Google Scholar 

  141. Yoon CH, Hur J, Park KW, et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation. 2005;112:1618–27.

    Article  PubMed  Google Scholar 

  142. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow—derived endothelial progenitor cells. J Clin Invest. 2001;108:399–405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Tepper OM, Capla JM, Galiano RD, et al. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood. 2005;105:1068–77.

    Article  CAS  PubMed  Google Scholar 

  144. Aicher A, Brenner W, Zuhayra M, et al. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation. 2003;107:2134–9.

    Article  PubMed  Google Scholar 

  145. Park SS, Caballero S, Bauer G, et al. Long-term effects of intravitreal injection of GMP-grade bone-marrow-derived CD34+ cells in NOD-SCID mice with acute ischemia-reperfusion injury. Invest Ophthalmol Vis Sci. 2012;53:986–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes. 2004;53:195–9.

    Article  CAS  PubMed  Google Scholar 

  147. Ingram DA, Lien IZ, Mead LE, Estes M, Prater DN, Derr-Yellin E, DiMeglio LA, Haneline LS. In vitro hyperglycemia or a diabetic intrauterine environment reduces neonatal endothelial colony-forming cell numbers and function. Diabetes. 2008;57:724–31.

    Article  CAS  PubMed  Google Scholar 

  148. Tan K, Lessieur E, Cutler A, et al. Impaired function of circulating CD34(+) CD45(−) cells in patients with proliferative diabetic retinopathy. Exp Eye Res. 2010;91:229–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Lee IG, Chae SL, Kim JC. Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy. Eye (Lond). 2006;20:546–52.

    Article  CAS  Google Scholar 

  150. Brunner S, Schernthaner GH, Satler M, et al. Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy: first in vivo data. Invest Ophthalmol Vis Sci. 2009;50:392–8.

    Article  PubMed  Google Scholar 

  151. Liu X, Li Y, Liu Y, et al. Endothelial progenitor cells (EPCs) mobilized and activated by neurotrophic factors may contribute to pathologic neovascularization in diabetic retinopathy. Am J Pathol. 2010;176:504–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Fadini GP, Sartore S, Baesso I, et al. Endothelial progenitor cells and the diabetic paradox. Diabetes Care. 2006;29:714–6.

    Article  PubMed  Google Scholar 

  153. Brunner S, Hoellerl F, Schmid-Kubista KE, et al. Circulating angiopoietic cells and diabetic retinopathy in type 2 diabetes mellitus, with or without macrovascular disease. Invest Ophthalmol Vis Sci. 2011;52:4655–62.

    Article  PubMed  Google Scholar 

  154. Khan ZA, Farhangkhoee H, Chakrabarti S. Towards newer molecular targets for chronic diabetic complications. Curr Vasc Pharmacol. 2006;4:45–57.

    Article  CAS  PubMed  Google Scholar 

  155. Sharma NK, Gardiner TA, Archer DB. A morphologic and autoradiographic study of cell death and regeneration in the retinal microvasculature of normal and diabetic rats. Am J Ophthalmol. 1985;100:51–60.

    Article  CAS  PubMed  Google Scholar 

  156. Yodoi Y, Sasahara M, Kameda T, Yoshimura N, Otani A. Circulating hematopoietic stem cells in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2007;48:5464–72.

    Article  PubMed  Google Scholar 

  157. Li Y, Reca RG, Atmaca-Sonmez P, et al. Retinal pigment epithelium damage enhances expression of chemoattractants and migration of bone marrow-derived stem cells. Invest Ophthalmol Vis Sci. 2006;47:1646–52.

    Article  PubMed  Google Scholar 

  158. Sasahara M, Otani A, Yodoi Y, Yoshimura N. Circulating hematopoietic stem cells in patients with idiopathic choroidal neovascularization. Invest Ophthalmol Vis Sci. 2009;50:1575–9.

    Article  PubMed  Google Scholar 

  159. Sasahara M, Otani A, Yodoi Y, Gotoh N, Kameda T, Yoshimura N. Circulating hematopoietic stem cells in patients with choroidal neovascularization secondary to pathologic myopia. Eye (Lond). 2009;23:718–26.

    Article  CAS  Google Scholar 

  160. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21:178–83.

    Article  PubMed  Google Scholar 

  161. Recchia FM, Scott IU, Brown GC, Brown MM, Ho AC, Ip MS. Small-gauge pars plana vitrectomy: a report by the American Academy of Ophthalmology. Ophthalmology. 2010;117:1851–7.

    Article  PubMed  Google Scholar 

  162. Park SS, Bauer G, Abedi M, et al. Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings. Invest Ophthalmol Vis Sci. 2014;56:81–9.

    Article  PubMed  CAS  Google Scholar 

  163. Siqueira RC, Messias A, Voltarelli JC, Scott IU, Jorge R. Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy: a phase I trial. Retina. 2011;31:1207–14.

    Article  PubMed  Google Scholar 

  164. Siqueira RC, Messias A, Voltarelli JC, Messias K, Arcieri RS, Jorge R. Resolution of macular oedema associated with retinitis pigmentosa after intravitreal use of autologous BM-derived hematopoietic stem cell transplantation. Bone Marrow Transplant. 2013;48:612–3.

    Article  CAS  PubMed  Google Scholar 

  165. Siqueira RC, Messias A, Gurgel VP, Simões BP, Scott IU, Jorge R. Improvement of ischaemic macular oedema after intravitreal injection of autologous bone marrow-derived haematopoietic stem cells. Acta Ophthalmol. 2015;93:e174–6.

    Article  PubMed  Google Scholar 

  166. Jonas JB, Witzens-Harig M, Arseniev L, Ho AD. Intravitreal autologous bone-marrow-derived mononuclear cell transplantation. Acta Ophthalmol. 2010;88:e131.

    Article  PubMed  Google Scholar 

  167. Jakob P, Landmesser U. Current status of cell-based therapy for heart failure. Curr Heart Fail Rep. 2013;10:165–76.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology & Vision Science, University of California Davis Eye Center, 4860 Y St., Suite 2400, Sacramento, CA, 95817, USA

    Elad Moisseiev M.D. & Susanna S. Park M.D., Ph.D.

Authors
  1. Elad Moisseiev M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanna S. Park M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanna S. Park M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Retina Division Chief; Department of Ophthalmology; Ahmanson Professor of Ophthalmology, Stein Eye Institute; David Geffen School of Medicine at UCLA, Los Angeles, California, USA

    Steven D. Schwartz

  2. Retina Division; Department of Ophthalmology, Stein Eye Institute; David Geffen School of Medicine at UCLA, Los Angeles, California, USA

    Aaron Nagiel

  3. Head of Astellas Global Regenerative Medicine, Chief Scientific Officer at the Astellas Institute for Regenerative Medicine, Marlborough, Massachusetts, USA

    Robert Lanza

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Moisseiev, E., Park, S.S. (2017). Autologous Bone Marrow-Derived Cell Therapies for Retinal Disease. In: Schwartz, S., Nagiel, A., Lanza, R. (eds) Cellular Therapies for Retinal Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-49479-1_7

Download citation

Publish with us

Policies and ethics

Search

Navigation